United Therapeutics Corporation - UTHR EV/Sales Multiple

Public company logo of United Therapeutics Corp (UTHR)

United Therapeutics is strengthening its position through strategic alliances with biotech laboratories to advance xenotransplantation. This chart of the company's enterprise value to revenue reflects business dynamics where an intellectual monopoly enables the sale of orphan drugs with high markups. Actual dominance in lung treatment ensures excellent profitability, while the 6821.48 indicator expresses the state of the business valuation metric excluding debt.

United Therapeutics - UTHR Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for United Therapeutics Corp (UTHR)

- money and cash flow information:
Initial company analysis:United Therapeutics, UTHR
Mass-produced product of United Therapeutics Corporation

This metric combines the market capitalization and net debt of United Therapeutics (UTHR), comparing the total enterprise value to the volume of generated revenue. By analyzing changes in the EV/Sales ratio, an investor assesses the premium for future growth, stripped of the impact of debt load. High values are justified by the company's technological dominance in pulmonary therapy and unique developments in organ bioprinting, which create an insurmountable barrier for competitors.